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ABSTRACT

An abstract of the thesis of Shin Chen for the Master of
Science in Biology presented July 6, 1994.

Title:

The DNA Sequence Required for the Maximal Transactivation of the VP5 Gene of Herpes Simplex Virus
Type 1.

A regulatory element involved in the transcriptional
activation of the major capsid protein (VP5) of herpes
simplex virus type 1 was identified and characterized in
this research project.

Gel mobility shift assay with

nuclear extracts from both uninfected and HSV-1 infected
HeLa cells identified two major protein-DNA complexes
involving the VP5 promoter.
found.

No viral specific complex

DNase I and orthophenanthroline-cu+ footprint

analyses in the same laboratory revealed that the two
complexes involve a single binding site, GGCCATCTTGAA,
located between -64 and -75 bp relative to the VP5 cap site.
To determine the function of this leaky-late binding site
(LBS)

in VP5 gene activation,

mutated VP5 promoters with

deletion and insertion around LBS were constructed and
linked to a reporter gene, bacterial chloramphenicol

2

acetyltransferase gene.

The effect of mutations were tested

in transient expression assay.

Deletion of LBS resulted in

seven to eight-fold reduction in the level of
transactivation of the chloramphenicol acetyltransferase
gene by superinfection with HSV-1 or by cotransfection of
HSV immediate-early genes. These results indicated LBS is
involved in the maximal transactivation of the VPS gene.

A

search of published gene sequences found the homologs of LBS
exist in a number of HSV-1

py

promoters, and other viral

promoters, as well as cellar promoters. Some of these
homologs have found involved in the transcription
regulation.
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CHAPTER I
INTRODUCTION
The herpesvirus family, Herpesviridae, contains nearly
100 viruses that infect different eukaryotic species, from
fungi to humansl.

It was named for those members who are

responsible for some common human diseases, the herpes
simplex viruses.

Herpesviruses also are found in other

living organisms, e.g. B virus of monkeys (occasionally
infect humans), pseudorabies virus of pigs, virus III of
rabbits, and oncogenic viruses that produce lymphoproliferative malignancies in chickens and monkeys.

Based on

host range, replication features and latency, Herpesviridae
is divided into three subfamilies: alphaherpesvirinae
(includes the herpes simplex type 1 and 2 viruses and the
varicella zoster virus), betaherpesvirinae (cytomegalovirus,
human herpesviruse 6 and 7), gammaherpesvirinae,
Barr virus).

(Epstein-

Within the subfamilies, viruses are further

divided into genera based on DNA sequence homology,
similarities in genome sequence arrangement, and relatedness
of virion proteins as demonstrated by immunologic methods.
Alphaherpesvirinae have a variable host range and short
reproductive cycle.

They spread rapidly in culture,

efficiently destroy infected cells, and cause latent
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infections primary in sensory ganglia.
have restricted host range.

Betaherpesvirinae

Their reproductive cycle is

long, and their infection progresses slowly in culture.

The

virus can be latent in secretory glands, lymphoreticular
cells, kidneys, and other tissues.

The gammaherpesvirinae

are specific for either T or B lymphocytes, and they
frequently exist as latent viruses in lymphoid tissue.
GENERAL BACKGROUND OF HSV
Seven herpesviruses have been isolated from humans,
herpes simplex virus type 1 (HSV-1) and herpes simplex virus
type 2 (HSV-2), varicella zoster virus (VZV), human cytomegalovirus (HCMV), Epstein-barr virus

(EBR), human

herpesvirus 6 (HHV 6) and human herpesvirus 7 (HHV 7).
Herpesviruses are very important for human beings.

In

America, over 87% of the population have been infected by one
or more herpesviruses.
Herpes simplex viruses

(HSV) were the first human

herpesviruses to be discovered and are one of the most
intensively investigated viruses.

Herpes simplex viruses

causes a wide variety of clinical infections, ranging from
inapparent infection and focal cytopathogenicity to fatal
encephalitis.

An interesting feature of these viruses is

their ability to establish a latent infection in neurons of
the sensory ganglia, here they persist for the life time of
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the host, and they may periodically be reactivated to cause
skin lesions and other disease symptoms.
As with many other known herpesviruses, HSV shares four
significant biological properties:
1) HSV characteristically encodes a diverse array of
enzymes involved in nucleic acid metabolism and DNA
synthesis.
2) Both the synthesis of viral DNAs and the assembly of
capsids occur in the nucleus.
3)

Irreversible destruction of the infected cell is the
consequence of infectious progeny virus production.

4) The viruses are able to become latent in neurons.
In some cases, the latent viral genomes take
the form of closed circular molecules and only one
viral gene region is expressed2.
Herpes simplex viruses type 1 and type 2 can be
distinguished by neutralization titration and by their
distinct clinical patterns.

Both types show cross reactivity

antigenically and share approximately 50% homology in their
genomes.

They differ in restriction endonuclease cleavage

sites and in the apparent sizes of viral proteins.
simplex viruses exhibit focal cytopathogenicity.

Herpes
The type 1

virus is primarily associated with oral and ocular lesions
and is transmitted by oral and respiratory secretions,
whereas type 2 is isolated primarily from genital and anal
lesions and is generally passed through sexual contact.
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Fever blisters or cold sores are the common diseases that
result from HSV-1 infection.

The more severe infection may

cause 1) disseminated disease to visceral organs, 2)

severe

deep ocular involvement which can lead to blindness, or 3)
herpes encephalitis.

HSV-2 is the causative agent for herpes

genitalis and generalized herpes of newborn.
frequently associated with cervical carcinoma.

It is also
For example,

HSV-2 has been isolated from 85% of the cervical carcinoma
patients.

HSV-1 usually establishes latent infection in

neurons of the trigeminal ganglia, whereas HSV-2 generally
become latent in sacral ganglia.
Virion structure
Herpes simplex type 1 is an enveloped virus of about
150 nm on diameter (Fig. 1).

As with all herpes virons, the

HSV-1 virion consists of four elements:
core,

(1) an electron dense

(2) an icosadeltahedral capsid surrounding the core,

(3) an amorphous tegument surrounding the capsid, and (4) an
outer envelope containing many viral glycoprotein spikes on
its surface.

The electron dense core is about 75 nm in

diameter, and it contains the linear, double-stranded DNA
genome of the virus.

The structural features of the capsid,

95 to 100 nm in diameter and comprised of 162 capsomeres, are
characteristic of all the herpesviruses.

The capsid is

composed of a number of viral proteins, at least eight of

which have been identified: VPS, VP19, VP21, VP22, VP22a,

•

DNA-protein
core

Envelope
g lycoproteins

Tegument

Icosahedral capsid

FIG. 1. Diagram of a virion of Herpes simplex virus.
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VP23, VP24, and 12 Kd protein.

The tegument, the granular

zone surround the capsid, contains the virion host shut-off
(vhs) protein, the a-trans-inducing factor
described as a-TIF,

(variously

ICP25, or VP16, a protein required for

activating immediate-early gene transcription),

immediate-

early proteins ICP4 and ICPO, and a very large protein (VPl)
associated with a complex that binds to the terminal "a"
sequence of the viral genome3,4.

The envelope is derived

from the inner membrane of the host cell nucleus modified by
the insertion of viral glycoproteins.

These glycoproteins

are gB, gC, gD, gE, gG, gH, gI, gJ, gK, gL and gM.
them

Three of

(gB, gD, and gH) are clearly indispensable for viral

replication, the rest of them are dispensable in cell culture
for both entering into cell and releasing from cells,

6

HSV-1 Genome
The genome of HSV-1 consists of one linear doublestranded DNA of 152 kilobasepairs with a molecular weight of
100 x 106 daltons.

It is composed of two regions, a long

region (L) and short region (S) which comprise 82% and 18% of
the viral DNA, respectively (Figure 2).

Each of these

regions consists of unique sequences bracketed by inverted
repeat sequences.

The repeats of long region are designated

ab and b'a', whereas the repeats of the short region are
designated a'c' and ca.

The number of a sequence repeats at

the L-S junction and at the termini is variable.

,

ab
I~

4

UL

c

•

IA

IA

H
Us

•
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. A

~111
II

~
ol u,

IA•
111111111
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Us~ CMV

UL
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a

~Us8 HSV
•
96x10
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IA 3

~
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u,

145x10•

TR, EBV
114x10•

l~~s Ill

FIG. 2. Diagrams of the physical structures of genomes of
several viruses of the family Herpesviridae.
The genomes
are composed of unique long (UL) and unique short (Us)
region. Terminal repeats (TR) bound the genome, and
inverted repeats (IR) bound the. unique regions.
(Dulbecco. 1988)
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The HSV-1 a sequence is approximately 85% G+C and 200
to 500 bp in length.

It contains 20 bp direct repeats on

each end and two unique segments separated by internal
directly repeated regions.

The structure of the terminally

repeated a sequence is highly conserved but contains a
variable number of internal repeat elements.

a sequence

The size of the

also varies from strain to strain.

The a

sequence is involved not only on recombination, but also in
processing and packaging the viral DNA.
During the replication, recombination occurs through
the inverted repeats of a sequence and gives rise to
different isomeric forms of the genome, and recombination is
closely associated with viral DNA replication7.

The ability

to exist as four linear isomers which differ in the relative
orientations of the long region and short region is a
property of herpes simplex virus shared, in part, with
several other

herpesviruses (Figure 3) .

Viral DNA prepared

from purified virion consists of four isomers present in
equal molar amounts.
(prototype),

These isomers have been designated as P

IL (inversion of the L region),

the S region),

Is (inversion of

ILs (inversion of both Sand L regions).

The

a sequence and viral trans-acting factors are required for
inversion.

The physiologic function of the inversion of L

and S regions is not clear. However, a HSV-1 mutant that is
locked in one orientation is perfectly viable8.

A.
a

I
4

b

I
L

b'

a' a'

c'

c

I

I

I

I

~4

S

FIG. 3. Schematic representation of the arrangement of DNA
sequences in the HSV genome. A. The domins of the L and S
components are denoted by the arrows. B. The four isomers of
the HSV DNA.

a

I
~
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Viral Replication
HSV-1 viruses have a rather wide host range of both in
vitro and in vivo.

Infection start with attachment which is

mediated by the binding of viral glycoproteins to heparan
sulfate moieties of cell surface, and enzymatically removal
of heparan sulfate from cell greatly reduced the level of
attachment and infection of those ce119.

Spear and

colleagues also showed that either glycoprotein gB or gC is
required for attachment.

Although gC is dispensable for

replication of HSV in cell culture,

it facilitates virion

adsorption to cells and enhances infectivity by about a
factor of 10 10.

The attachment activates a penetration

process mediated by viral surface proteins which cause the
fusion of the viral envelope with the cell plasma membrane.
Glycoproteins gB, gD and gH are indispensable for the fusion
of the viral envelope and cell membrane 11, 12, 13.
After penetration, the viral nucleocapsid is
transported along the cytoskeleton from the site of entry to
nuclear pores.
nucleus.

There the viral DNA and is released into the

There are virion components protect and facilitate

the entry of the DNA into cells, and also appear to be
involved in the early shut off of host macromolecular
synthesis. The linear, double-stranded viral DNA circularizes
immediately upon release from capsid.

Once in the nucleus,

the viral DNA is transcribed by host RNA polymerase II with
the participation of various viral and cellular factors.

HSV

11
mRNAs are capped, methylated, and polyadenylated, and only
small proportion of viral mRNAs are derived by splicing.

The

abundance and stability of the various HSV-1 mRNAs appear to
vary.
Viral DNA synthesis is carried out by viral proteins
and host cell enzymes in nucleus.

There are three origins of

DNA replication: two in the terminal repeat sequences of
short region, between the promoters of ICP4 and ICP22(ori 1)
or ICP4 and ICP27(ori 2), and one(ori 3)

in the middle of the

unique long region between the genes encoding the DNA
polymerase and the DNA binding protein (ICP8)14.

By

transfecting cells with a plasmid containing an origin of DNA
synthesis and various fragments of the HSV genome, genetic
studies have shown that seven genes are essential for HSV
origin-dependent DNA replication: UL9 encodes an origin
recognition protein15; ULS, UL8, and UL52 encode the three
subunites of a helicase-primase complex16; UL29 encodes a
single-strand DNA binding protein ICP817; UL30 encodes a DNA
polymerase18; and UL42 encodes a double-strand DNA binding
protein that is a subunit of DNA polymerasel9.
The translation of viral mRNAs occurs in the cytoplasma
on both bound and free polyribsomes.
seem to be processed extensively.

Most of the proteins

Processing includes

cleavage, phosphorylation, sulfation, glycosylation poly(ADPribosyl)ation, and nucleotidylylation.

Structural proteins
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and most regulatory proteins are transported into the nucleus
where new capsid assembly occurs.
The concatemeric viral DNA synthesized by a rolling
circle mechanism is cleaved at terminal repeats in the a
sequence and packaged in preformed capsid.

These particles

are unstable and noninfectious until they acquire envelope.
Unlike other enveloped virus, the envelopment occurs at the
inner lamella of the nuclear membrane which has been modified
by viral glycoproteins.

The release of virus does not occur

by budding from plasma membrane, rather through the cisternae
of the endoplasmic reticulum which extend to the plasma
membrane (see Figure 4)
HSV-1 GENE EXPRESSION
The cascade of HSV-1 gene expression
The DNA sequence of the 152-kilobase genome of herpes
simplex virus type-1

(HSV-1) has been determined.

at least 72 unique proteins20,21.

It encodes

Fifty six of the open

reading frames are in UL region, twelve are in Us and one
each in the repeat regions.

Although the function of many of

these genes has been determined, there are still many whose
function in either viral replication or viral pathogenicity
is not known.

The transcription of viral DNA takes place in

the nucleus by host RNA polymerase II and all viral proteins
are synthesized in the cytoplasm.

During the productive

infection, the synthesis of these proteins is temporally and
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FIG. 4. Sequence of events in the multiplication of
herpes simplex virus from entry of the virus into the
cell by fusion of the virion envelope with the host
membrane to assembly of virions and their exit from the
cell through the endoplasmic reticulum. (Dulbecco 1988)
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quantitatively regulated, primarily at the transcriptional
level by cis-acting signals within the viral genome and
trans-acting factors encoded in both the host and viral
genomes22,23.

Based on this cascade fashion of gene

expression, the viral genes were classified into three
kinetic classes which were designated as immediate-early
(alpha), early (beta), late (gamma)24, 25.
Alpha genes are those that are expressed in the absence
of viral protein synthesis.

The synthesis of a polypeptides

reaches maximal rates at approximately 2 to 4 hours postinfect ion and they accumulate until late in infection.

HSV-1

encodes four a proteins which have been shown to affect the
expression of HSV-1 genes, namely,
ICPO

(IEllO), ICP4 (IE175),

infected cell polypeptides

ICP22 (IE68), and ICP27 (IE63).

The function of the fifth a protein,

ICP47

(IE12), has not

been established, but does not appear to affect HSV-1 gene
expression in tissue culture26.

In addition to the five a

genes, the latency-associated transcript 1 (LATl) and a
transcript designated as Oris RNA are transcribed under a
conditions(i.e. in the absent of protein synthesis).
Beta genes are not expressed in the absence of a
proteins and their expression is enhanced in the presence of
inhibitors of viral DNA synthesis.

The

P transcripts

can be

detected 2 hours postinfection. Their synthesis reaches
maximal rate following the initiation of DNA replication,
about 5 to 6 hours post-infection and gradually decrease to

15
nearly undetectable levels late in infection.

Subgroup ~1,

that includes ICP6 (ribonucleotide reductase) and ICP8

(the

major DNA-binding protein), are expressed earlier than
subgroup ~2 which includes ICP36 (viral thymidine kinase) and
HSV DNA polymerase.

The

P genes

primarily encode products

required for DNA synthesis, and the appearance of their
products signal the onset of viral DNA synthesis (about 2 to
3 hours post-infection) .
The expression of late genes require the prior a and
gene expression.

P

Late genes specify virion structural

proteins and have been divided into two subgroups, py(or yl)
and y(oril.), based on the sensitivity of their expression to
DNA inhibitors.

Low level of py genes (gB, gD and VPS)

transcripts are detectable prior to viral DNA synthesis,
whereas essentially no y gene (e.g. gC, USll and UL38)
transcription is observed.

Following the initiation of viral

DNA replication, 2 to 3 hours post-infection, both

py

and y

expression increase and reach peak level at 7 to 8 hour postinfection and remain at high level late in infection.

Regulation of HSV-1 gene expression
The regulation of HSV-1 gene expression has become a
major focus of research, and the mechanism by which the virus
regulates its replication remains an exciting area of
investigation.
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The expressions of a genes are induced by a-TIF (Vmw65
or VP16), which is a virion phosphoprotein synthesized late
of infection and incorporated into tegument during virion
assembly.

When a-TIF is released into infected cell, it

induces viral immediate-early gene expression via two
cis-acting elements, the TAATGARAT and GCGGAA consensus
sequences present in the IE promoters27( see figure 5).
Alpha-TIF does not bind to DNA itself, but it forms a complex
with cellular transcriptional factor Oct-1 (NFIII, OTF-1),
and Oct-1 directly bind to the consensus sequences of IE
promoters.

Kristie and Sharp demostrated that at very high

concentration, a-TIF could form complexes with DNA in the
absence of Oct-128.

This function is dispensable in tissues

culture at high multiplicity, but is required for normal
virus replication at low multiplicity of infection.
Therefore, the IE gene expression is not totally dependent on
the activity of a-TIF.
All immediate-early proteins except ICP47 are nuclear
phosphoproteins, and they regulate their own synthesis as
well as the protein synthesis of other kinetic classes.
Studies using viral ICP4 gene mutant have shown that ICP4 is
involved in autoregulation of its own expression as well as
that of other a genes, and it activates of
expression29, 30.
and

Transcription of

p

p, py,

(ICP8),

y (gC) genes is dependent on rcp431, 32.

py

and y
(ICP5, gB),

ICP4 represses

expression from its own promoter and the ICPO promoter by

CASCADE REGULATION OF HSV-1 TRANSCRIPTION

Trans-inducing factor
(VP16)

DNA Replication
I
I

+

\+

I
I
I
I

--i~

+
-.....:.---~~.\
E(J3)

~Regulatory
proteins

FIG. 5.

Involved in
DNA replication

LL (J3y) , L (y)

-'~
I
I

I
I

Structural
proteins

Diagram of the cascade regulation of HSV-1 transcription.
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binding to a specific sequence, ATCGTC, near the
transcriptional start site33, 34, 35.

Mutations which

eliminated DNA binding of ICP4 also eliminated or reduced
both ICP4 transactivation and autoregulation indicating that
DNA binding of ICP4 is required for these functions36.
Studies have shown that HSV-1 infected cells that expressed
defective ICP4 failed to: 1) activate the transcription of
early and late genes, 2) induce viral DNA synthesis, and 3)
down regulate immediately-early gene expression37.
~

tk, a

The HSV-1

gene is efficiently expressed only in the presence of

IE gene products38.

Faber and Wilcox's studies have

attempted to define the tk promoter domains required for ICP4
induced expression.

None of the tk sequences that interact

with ICP4 contains a consensus binding site for ICP4.

This

result suggest the ability of ICP4 to interact with more than
one DNA sequence.
ICP27 is an essential gene which has both activator and
repressor functions.

In the absent of functional ICP27,

a

genes are overexpressed, whereas the viral DNA replication
reduced and late genes poorly expressed.

In transient assay,

ICP27 appears to have little or less effect alone on most
HSV-1 promoters, but has two different effects on combination
with ICPO and ICP4, depending on the target genes.

A strong

repression was observed in transfection of immediate-early
(ICPO,

ICP27), early (TK), and leaky-late(gB, gD) and late

(gC) promoters with these three IE, whereas increased

19
transactivation were shown with a early promoter (alkaline
exonuclease) and a leaky-late promoter (VP5)39,

40.

Analysis

of the mutant phenotypes demonstrated the genetic evidence
for these two distinct transactivation functions of rcp2741,
42

Cells infected with deletion mutants of ICP27 synthesize

viral DNA, but late genes (y) are not expressed43.

Sandri-

Goldin, et al. recent study showed the major effect of ICP27
appears to be at post-transcriptional leve144.
In contract to ICP4 and ICP27 which were absolutely
essential for virus replication, ICPO deletion mutant grow as
well as wild-type virus and produce same amount of viral
proteins at high multiplicities of infection, but grow poorly
and produce a less amount viral proteins at low multiplicities.

Therefore,

viral production cycle.

ICPO is important but not essential in
Transient expression assays have

shown that ICPO is a strong trans-activator of all classes of
viral HSV-1 genes as well as a number of cellular genes.

The

mechanism by which ICPO transactivates viral and eukaryotic
promoters is unclear.

Available evidence shows that ICPO

activates many promoters although it does not appear to
require any cis-acting element for this activity45.

ICPO and

ICP4 can stimulate expression of HSV-1 early and late
promoters synergistically, since increased levels of
induction have been observed when both are present than with
either one alone46, 47
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There is no evidence indicating that ICP22 or ICP47
affect viral gene expression in transient expression assay,
although in certain cell types ICP22 is essential for
efficient viral replication and late gene expression48.
The

~

genes are under the control of promoters that are

active at low levels in uninfected cells or high levels in
infected cells.

The

p promoters

are activated by ICP4 and

ICPO, or can be stimulated by exogenous enhancers (e.g.
simian virus 40)49.

Most of

p gene

products are proteins

involved in viral DNA synthesis, and may have both positive
and negative regulatory functions.

Godowski and Knipe have

suggested that in addition to its DNA binding function,

ICP8

may be important, also, in the maintenance of the highly
ordered cascade of viral gene expression since defects in the
ICP8 protein result in increased mRNA level of a (ICP4),
(ICP8),

py

(ICPS) and

y

(gC).

p

ICP8 is required for shut-off

of transcription of ICP4 and decrease in the transcription of

p, py

genes.
The promoter structure of late genes is least

understood and highly varied.

Late genes do not appear to be

efficient-ly expressed in uninfected cells. Temperature
sensitive mutants studies have shown that ICPO,

ICP4 and

ICP27 are essential for efficient expression of late
promoters.

Except for an ICP4 binding site in the gD

promoter50, extensive mutational analyses have not uncovered
cis-acting sequences in leaky late promoters that are
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specifically required for activation by IE proteins.

The

TATA element is the only consensus sequence identified in the
upstream regulatory region of true late promoters51.
Deletion studies have indicated that little upstream sequence
from TATA element is required for efficient expression of
true late genes, but sequences downstream from the TATA
element are important even though no consensus sequence have
been identified52.

Homa et al. suggested that true late

promoter activity requires a specific type of TATA element,
since tk TATA box was unable to function when it was moved to
the gC locus.

The inhibition of viral DNA replication causes

a moderate reduction in the accumulation of
strong reduction of the accumulation of

~y

mRNAs and a

y mRNAs53.

THE GENE OF MAJOR CAPSID PROTEIN
The architecture of capsid is one of the characteristic
features of the herpesvirus family.

Capsid consists of 150

hexavalent capsomers which form the edges and faces of the
icosahedron and 12 pentavalent capsomers that are located at
the capsid vertices.

There are three distinct types of

capsids that can be isolated from the nuclei of herpesvirus
infected cells.

Type A are the capsids that lack DNA and are

never enveloped; type B contains DNA but are never enveloped;
type C contains DNA and are obtained by de-enveloping intact
virus.

Empty capsids consist of five proteins, VPS, VP19C,

VP23, VP24, and a small protein54; type B capsid contains two
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additional proteins, VP21 and VP22a; instead of VP22a, type C
capsid contains VP22.
The major capsid protein (VP5) constitutes
approximately 60% of the total capsid B mass and is
considered to be the basic component of the hexavalent
capsomers.

In 1979, Anderson et al. reported that a 6 Kb

mRNA was the most abundant viral transcript associated with
polyribosome late in infection.

In 1981, Costa et al. mapped

this 6 Kb mRNA between 0.23 and 0.27 map units of the viral
genome (Figure 6).

In 1984, this 6 kb mRNA was able to be

translated in vitro into a protein with molecular weight of
155,000.

By using a polyclonal antibody made against

purified HSV-1 VP5, Costa et al. confirmed the product of 6
Kb mRNA was the major capsid protein VP5.
The gene encoding VP5 belongs to leaky-late or

~y

class.

Like true late genes, the promoter structure of leaky-late
genes and the requirements of leaky-late gene expression
remain mostly mystery.

Despite the requirement of DNA

replication for maximal expression, the VP5 promoter has all
the features of a typical eucaryotic transcriptional
promoter, and it has served as a good model for the
genes.

VPS promoter is inactive in uninfected cell.

~y

class
In a

transient assay using a reporter plasmid, the VPS promoter
was not active in uninfected cells55.

In addition, a HeLa

cell nuclear transcription extract did not initiate
transcription of VPS under the conditions in which ~ gene

LOCATION OF VPS IN HSV-1 GENOME
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FIG. 6. (a) Location of Kpn I i fragment in the HSV-1
genome (Preston et al., 1978). (b) Location of VPS mRNA
in Kpn I i fragment. The size of the mRNA are indicated
above the transcripts. The kinetic class and apparent
molecular weights(x103) of in vitro translation products
are indicated below the transcripts. (c) Location of
protein coding regions in Kpn I i. Each open reading
frame is shown as an open arrow. The approximate
molecular weights of encoded proteins are indicated.
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transcription was initiated.

However, a VPS promoter was

readily transactivated in transient expression assay either
by HSV super-infection or a gene ICPO,
cotransfection56, 57.

ICP4, and ICP27

The level of activation of VPS

promoter was directly proportional to the level of ICP4
expressed in the cell line58.

In addition to IE proteins,

studies using inhibitors of viral DNA synthesis have shown
that the viral DNA replication was also required for VPS
maximum expression. But the mechanism

of this coupling is

unclear.
Detailed studies of the expression of a reporter gene
under the control of various length VPS promoters in
transient expression assays showed that 75 bp upstream
sequence of VP5 promoter was active at low levels in
uninfected cells, and it was sufficient to allow higher
expression with HSV super-infection even though the
expression level was lower than the maximum level driven by
125 bp of upstream sequence of the VP5 promoter.

DNA

sequence between -75 to -125 relative to the cap site
repressed the activity of VP5 promoter in uninfected cells,
but it was required for maximum level of transactivation by
superinfecting virus or by cotransfected IE genes39.

R. H.

Costa and E. K. Wagner suggested that all the modification of
host cell's transcriptional machinery required for maximum
expression of the VPS gene is accomplished by IE or E gene
products or both, since inhibition of viral DNA synthesis
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increased CAT gene expression driven by VP5 promoter in
infected cells.
GOAL OF THIS STUDY
One of the major goal of herpes virus studies is to
prevent not only the primary infection but also the recurrent
infection.

To achieve this goal, it is necessary to

understand the molecular biology and pathogenesis of HSV
infection.

Studies of HSV gene regulation provides a major

step towards this understanding.

The regulatory mechanisms

of late gene expression are less well characterized than
those of immediately early genes and early genes.

VP5

promoter contains all the features of a typical eucaryotic
transcriptional promoter.

It is a good model for a leaky-

late gene in which the interaction of viral and cellular
transcriptional factors and viral DNA control sequences can
be studied.
In the early studies of VPS promoter by other
laboratories, viral IE proteins, ICPO,

ICP4,

found to be required for transactivation.

ICP27, were

But exactly how

the three IE proteins transactivated VPS promoter, what cisacting sequence required, and if any cellular transcriptional
factor(s)

involved are unknown.

By using mobility shift,

competition binding assay, deletion mutant analysis and
transient expression assays,

I have carried out a series of

studies to characterize and determine the function of viral
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and cellular factors, and the DNA sequences involved in the
regulation of HSV-1 leaky late gene expression.

These are

the questions I have asked in this research project:
1) How do the

HSV-1 Immediately-early proteins ICPO,

ICP4, and ICP27 transactivate the VPS promoter?

Is

there any DNA sequence in the promoter that directly
binds to viral protein(s)?

Can any of the three

protein be dispensed?
2)

Is there any cellular factor(s)
transactivation?

involved in the

Are there specific HSV-1 VPS

promoter sequences involved?

How important is

this DNA sequence in affecting the VPS promoter
activity in both uninfected cells and HSV-1 infected
cells?
3)

Is there any homology between the VPS binding site
identified and other HSV ~y gene promoter sequences?
Do they form the same or similar protein complexes?

4) Do homologous or similar regulatory DNA sequence
exist in other viruses?

Is the same, or similar,

cellular factor associated with them?

What do we

know about the function of this cellular factor?

CHAPTER II
MATERIALS AND METHODS
MATERIALS
Plasmids
pVP5(-4/-168)CAT, pVP5(-4/-75)CAT and pVP5(-50/-168)CAT
were kindly provided by E. Blair and E. Wagner, University of
California,

Irvine, CA.

These plasmids contain VPS prornter

-4 to -168, -4 to -75, and -50 to -168,

respectively,

linked

to a reporter gene, the bacterial chloramphenicol acetyltransferase

(CAT) gene and the EcoRI/SalI fragment of pBR322

in which the 940 bp poison sequence was removed.

The map of

pVP5(-4/-168)CAT is shown in Figure 7, the wild type VPS
promoter structure and sequence are shown in Figure 8.
pGRlSOB was kindly provided by G. Hayward, Johns Hopkin
University. pGR150B is comprised of the 23.7 kb BglII-HM
fragment of HSV-2(333) which contains genes for irnrnediatelyearly proteins IE175,

IEllO,

IE63 cloned into the BamHI site

of pBR322·
All of plasmid DNA were prepared by an alkaline lysis
procedure of Brinboim and Doly59 .

Enzymes
Restriction endonucleases used in this project were
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FIG. 8. A. Schematic representation of VPS promoter structure.
of VPS promoter.

B. The DNA sequences
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purchased from Bethesda Research Laboratories,
England Biolab.

Inc. and New

They were used with the appropriate lOX

reaction buffer supplied by the manufacturer.
Exonuclease BAL 31, purchased from United States
Biochemical Corporation, was used for exonucleolytic
digestion.

The Klenow fragment of DNA polymerase I, T4 DNA

ligase, and RNase A, purchased from Bethesda Research
Laboratories, Inc., were used for radioisotope labeling of
DNA and construction of VPS promoter mutants.
Radioactive Isotopes
[a-32p]dCTP was purchased from NEN Research Products,
Inc. at 3000 Ci/mmol.

3H-Na0Ac, 3.3 Ci/mmol, 10 mCi/ml was

also purchased from NEN Research Products, Inc.
Cells and Media
Hela cells
Collection.

(CCL2) were from American Type Culture

Dulbecco's Modified Eagle (DME) medium,

penicillin and streptomycin were purchased from GIBCO
laboratories, Inc.

Bovine calf serum and fetal bovine serum

were purchased from Hyclone Laboratories,

Inc.

Virus
The vhs-1 mutant of HSV-1
G. S. Read.

(KOS) was kindly provided by

It was derived by bromodeoxyuridine mutagenesis

and it is defective in the virion associated host shut-off
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function responsible for the initial suppression of host
protein synthesis.
Nuclear Extract
The nuclear extracts were kindly provided by Rosemary
Lawn.

They were prepared according to the procedure of

Dignam et a1.60 from HeLa cells that were either mock
infected or infected with HSV-1 for 8 hours.
PREPARATION OF DNA PROBES
Restriction digestion and DNA fragment isolation
Plasmid DNA was mixed with 1/10 total volume of lOX
reaction buffer and 2-4 units restriction enzyme per µg DNA.
Sterile distilled water was added to keep the enzyme
concentration at or below 1/10 total volume and to dilute the
lOX reaction buffer to lX concentration. The mixtures were

incubated at 37°C, with the exception of BstNI which required
60°C, for 2-6 hours.

The incubation time depended on the

activity of each enzyme (information provided by BRL) .
Reactions were stopped by the addition of 1/10 volume of lOX
stop-dye (50%

(w/v) sucrose, 0.2 M EDTA, 0.25% bromphenol

blue, 0.25% xylene cyanol FF).

Samples were heated at 65°C-

700C for 3 minutes to prevent the annealing of cohesive
termini and immediately chilled on ice and loaded into
horizontal agarose gels.

Agarose concentration in TBE buffer

(0.089 M Tris-Cl, 0.089 M Boric acid, 0.02 M EDTA pH 8)
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varied from 0.8-2.5% depending on the size of fragments.

Gel

was submerged in TBE buffer and run at 800-900 volt hours.
Each gel also was loaded with known size markers along with
DNA samples.

The markers were bacteriophage lamda DNA

digested with HindIII and PBR322 digested with AluI.
Following electrophoresis, gels were stained for 10 minutes
with 0.1 µg/ml ethidium bromide, destained for 10 minutes
with water, then visualized under a long wave UV light, and
photographed with Polaroid instant pack film 667.
DNA fragments were isolated by electrophoresis onto DE81
paper, and elution from 1 M NaCl, 0.1 mM EDTA,
pH 8.

10 mM Tris-Cl

The eluted DNA was extracted, once with phenol and

chloroform (PCIA), once with chloroform and isoamyl alcohol
(CIA), precipitated with ethanol, and redissolved in 0.089 M
Tris-Cl pH 7.8,

0.089 M EDTA (TE) buffer to achieve the

desired concentration61.

DNA fragment concentration was

estimated by electrophoresis on an agarose minigel along with
different amounts of known DNA markers, and comparing the
relative ethidium bromide staining intensities.

DNA Labeling
The 168 bp HindIII/SalI fragment of VP5(168)-CAT was
isolated and labeled with [a-32p]dCTP by Klenow fill-in
reaction62 as follows: DNA probe (0.5 µg)

was mixed with 1/10

volume of lOX nick translation buffer (0.5 M Tris-Cl pH 7.2,
0.1 M Mgso 4 , 1 mM dithiothreitol, 500 µg/ml bovine serum
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albumin) and 0.1 nmol of dATP,dTTP, dGTP, and 7.5 µCi
32p]dCTP,

[a-

6-8 units of Klenow fragment in a total volume of

40 µl. The mixture was incubated at 37°C for 30 minutes and
cold chased by incubation with 2 mmol of dATP, dCTP, dGTP,
and dTTP for another 15 minutes.
to stop the reaction.

One µmol of EDTA was added

Following the Klenow fill-in reaction,

the sample was extracted with PCIA and CIA, unincorporated
nucleotides were removed by gel filtration through an 1 ml
Sephadex G-50 spun column.

The amount of [a-32p]dCTP

incorporated during the Klenow fill-in reaction was measured
by trichloroacetic acid (TCA) precipitation using a
modification of procedure provided by Maniatis et al.
MOBILITY SHIFT ASSAY
A modification of gel mobility shift assay of Fried, M.
and D. M. Crothers, was used to detect binding of potential
regulatory proteins to the VP5 promoter region63.
0.1-1.0 ng of DNA probe were mixed with 1.3 to 6.2 µg
nuclear extract from either mock infected or HSV-1 infected
Hep-2 cell in the presence of varying amounts
of poly(dI-dC).

(4 to 13.5 µg)

Reaction buffer was added to achieve the

final concentration of 6 mM Tris-Cl, pH 7.9, 40 mM KCl, 2 mM
EDTA, 0.2 mM DTT, 8% (v/v) glycerol in a total volume of
20ul.

Reaction mixture were incubated at 37°C for 30

minutes.

Two µ1 of 0.25% bromphenol blue were added and the

reaction mixture were analyzed by electrophoresis through 4%
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polyacrylamide gels (acrylamide:bisacrylamide weight ratio of
30:1) in 25 mM Tris-Cl, 25 mM Boric acid, 1 mM EDTA at 4°C.
Gels were electrophoresed at 250 volts with buffer
recirculated until bromphenol blue had run to the bottom of
the gel, about 2 to 2.5 hours, and they then were transferred
to Whatman 3MM paper, dried and autoradiographed with Fuji RX
film with intensifying screen at -70°C for 24 hours.

To

quantify the amount of complexes formed, the intensity of
each band was measured by LKB 2202 ultrascan laser
densitometer.
COMPETITION BINDING ASSAY
A number of different viral and cellular promoters were
tested for their ability to compete with protein binding to
the VPS promoter.

The competitors are listed in Table 2.

Reaction conditions were as described in the gel mobility
shift assay procedure except that the various nonradioactive
competitor DNAs were added in 10-50 fold molar excess over
the labeled DNA probe.
PREPARATION OF MUTATED VPS PROMOTER CONSTRUCTS
Strategy for construction of promoter mutations
In order to test the function of the protein binding
sequence of VPS promoter found in mobility shift assay,

I

constructed a series of pVP5(168)-CAT mutations in which the
protein binding sequence was partially or completely deleted
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and the adjacent NF-1 consensus sequence was split.

The

strategy used for these construction is shown in Figure 9.
Fragment 1 was prepared by linearizing pVP5(168)-CAT 90
ug with 180 units of SalI in a total volume of 250 ul.

This

fragment was subjection to digestion with exonuclease BAL 31
as follows: First, a pilot reaction was run in order to
determinate the exonuclease rate.
µg)

Linearied plasmid DNA (8.3

was incubated at 30°C with 6 µ1 of Sx BAL 31 buffer (3 M

NaCl,

60 mM MgCl2,

60 mM CaCl2, 100 mM Tris-Cl pH 8, 5 mM

EDTA) and 2.25 units of BAL31 exonuclease.

Fractions of 3 µl

removed at 0, 2, 4, 7, 10, 15, 20, 30, 40 seconds, were
subjected to electrophoresis in an 0.8% agarose gel.
measuring the fragment size in each fraction,

By

I determined

that approximately 125 bp at each end of the fragment were
deleted within 40 seconds.
Following the same procedure, 113 µl of the remaining
linearized DNA were subjected to exonuclease BAL31 deletion.
According to the deletion rate, fractions of 27 µl were taken
after 23, 26, 29, 32, 35, 38 seconds of incubation.

Three µ1

of 0.5 M ethyleneglyclo-bis-<P-amino ethyl ether)N,N,N,N,tetracetic acid (EGTA) pH 8 was added to each fraction to
stop the reaction.

All fractions were pooled into one tube

and extracted with PCIA and CIA, and then precipitated with
ethanol.

The dry DNA pellet was resuspend in 10 µl TE.

Deleted fragments were digested with NcoI and fragments of
617-642 bp were isolated by electrophoresis in a 1% agarose
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gel.

The deleted/NcoI fragments were polished by filling in

any non-blunt ends with the Klenow fragment according to the
nick translation procedure as described above.
BglII linker was purchased through New England Biolabs,
Inc.

T4 polynucleotide kinase and 5x kinase buffer, T4 DNA

ligase and 5x ligase buff er were purchased from Bethesda
Research Laboratories.

BglII linker was phosphorylated by

incubation with 1 µ1 10 mM ATP, 20 units T4 polynucleotide
kinase and 1/5 volume supplied 5x kinase buffer at 37°C for
30 minutes.
Ligation protocol was provided by Maniatis et al.
deleted NcoI fragment

(6.9 µg)

The

and 1.25 µg BglII linker were

mixed with Sul of 5x ligation buffer and 7 units of T4 DNA
ligase, sterile distilled water was added to bring final
volume to 25 µl.

The mixture was incubated in l6°C for 16

hours and the reaction was stopped by addition of one half
volume of 7.SM NH40Ac.

Three volumes of absolute ethanol

were added and the DNA was allowed to precipitate at -20°C
for 1 hour.

The DNA was pelleted by centrifugation at

10,000xg for 30 minutes at 4°C, vacuum dried.

The DNA was

digested with NcoI and BglII to generate NcoI/BglII fragments
of 650-625 bp.

These fragments were purified by gel

electrophresis and isolated as described above.
Fragment 2 was prepared by digesting 50 µg of pVP5(168)CAT plasmid with EcoI and XbaI.

The 1200bp EcoRI/XbaI

fragment was isolated and partially restricted with BstNI by

controlling the incubation time.
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The mixture of 78 bp and 95

bp BstNI/Xba I fragments was isolated by gel electrophoresis.

After a Klenow fill-in reaction to make blunt

ends, phosphorylated BglII linkers were ligated to these
BstNI fragments.

Subsequent digestion with Bgl II and Sall

generated the 84 bp and 101 bp BglII/SalI fragments.
Fragment 3 was prepared by digesting 10 µg of pVP5(168)CAT plasmid with NcoI and Sall.

The 3020 bp NcoI/SalI

fragment was isolated by agarose gel electrophoresis.
By using the same ligation procedure, equal molar
amounts of fragments 1, 2 and 3 were ligated together using
0.16 µg fragment 1, 0.02 µg fragment 2, 0.81 µg fragment 3,
and 1 unit of T4 ligase in a total reaction volume of 16.9
µl.

Ligation reaction was carried out at +4°C for 16 hours.

The ligation mixture was stored at -70°C.
Selection of mutants
Transformation. Competent HB101 cells were purchased
through Bethesda Research Laboratories Inc.
tion procedure was also provided by BRL.
were diluted in TE (1:10).

The transforma-

Ligation mixtures

Aliquots of 0.8 µl that contained

5 ng ligated VPS DNA were added to 20 µl HB101 cells and the
mixtures were incubated on ice for 30 minutes.

After 40

seconds of heat shock in a 42°C water bath, the mixtures were
chilled on ice for 2 minutes, then 80 µl SOC buffer (2%
bacto-tryptone, 0.5% Yeast extract, 10 mM NaCl, 2.5 mM KCl,
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10 mM MgCl2, 10 rnM MgS04, 20 mM glucose) was added and the
mixture was shaked at 225 rpm for 1 hour at 37°C.

Two

additional transformation mixtures, one with the pBR322 DNA
and the other without any DNA, served as controls.

The

transformation mixtures were streaked out on Luria Broth
(LB) agar plates with 100 ug/ml ampicillin.

To test the

viability of HB101 competent cells, 20 µ1 of cells diluted
into 100 µl of water were spread out on a LB agar plates
without ampicillin.

All plates were incubated overnight at

37°C.
Restriction analysis.

From the transformation, forty

three ampicillin resistant colonied were picked and
innoculated separately in 4 ml of Luria broth containing 50
µg/ml ampicillin.

Plasmid DNAs were prepared from each clone

by a quick plasmid preparation.

Each sample was analyzed by

restriction endonuclease digestion.

Pstl was used to

linearize mutated DNA, EcoRl and Sall were used for three
cuts, and EcoRl, Sall and Bglll provided four cuts in the
recombinant plasmids.
From the restriction analysis, eight mutant clones which
appeared to contain the desired range of deletions in the VP5
promoter sequences were selected.
DNA sequencing.

The plasmid DNAs from eight pVP5(-4/-

168)CAT mutants were obtained by large scale plasmid DNA
preparation.
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i. Preparation of labeled DNA fragments
The plasmid DNA from pVP5(-4/-168)CAT and its mutants
were linearized by SalI digestion and labeled with [a32p] dCTP by Klenow fill-in reaction as described above.
After a second digestion with PvuII, 32P-labeled SalI/PvuII
fragments,

ranging from 290 to 317 bp, were isolated from

agarose gels.
ii. DNA sequencing
A modification of Maxam-Gilbert protoco164, was used to
determine the DNA sequences of mutated VPS promoters.

For

each end-labeled DNA fragment, a set of four reactions were
set up: a) methylation of the DNA with dimethyl sulfate for
cleavage at G sites. b) partial depurination in sodium
formate provide in approximately equal cleavage at G sites
and A sites. c) treatment with hydrazine for cleavage at C
and T sites. d) treatment with hydrazine and sodium chloride
to cleave only at C sites.
Five µ1 of each sequencing reaction was loaded onto an
8% polyacrylamide gel (acrylamide:bisacrylamide ratio 28:1,
7.7 M Urea}.

Electrophoresis was carried out at 1500-2000

volts until the loading dye moved approximately two-thirds of
the way down the gel.

Gels were fixed in solution of 95%

acetic acid and 5% (v/v) methanol for 10 minutes, and
transferred to Whatman 3MM paper, vacuum dried, exposed to
Fuji RX film for 48 hours at -70°C with KODAK intensifying
screen.
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TRANSFECTION AND CAT ASSAYS

Transfection
Four mutated VPS promoter constructs were selected for
analysis.

They were #2 in which the sequence from -83 to -93

was replaced by BglII linker, #6 in which the BglII linker
was inserted into the BstNI site in the NF-1 consensus
sequence, #10 in which NF-1 site and half of the binding
sequence were deleted, and mutant #13 in which NF-1 site and
the binding sequence were completely deleted.

(see Fig. 10).

These mutant plasmids, along with the wild type pVP5(-4/168)CAT, were tested in transient-expression assays for CAT
gene expression.
Hela cells

(CCL2)

from American Type Culture Collection

were propagated in Dulbecco's Modified Eagle (DME) medium
containing 10% heat inactivated calf serum and 100 units/ml
of penicillin, 100 µg/ml of streptomycin at 37°C, under a 5%
C02 atmosphere.

They were routinely passaged every 5 days at

a 1:15 split ratio.
Hela cells were seeded in 35-mm six-well cluster dishes
at 3xl05 cells per well approximately 20 hours before
transfection.

After 17 hours, the medium was removed and

cells were re-fed with 2.5 ml DME containing 10% heat
inactivated fetal cattle serum and penicillin(lOO unit/ml)
and streptomycin(lOO µl/ml)

(DME+l0% IFCS+P/S).

Three hours

later, each 35 mm well of subconfluent monolayer was
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transfected with 0.5 ml DNA-calcium phosphate coprecipitates
which contained 5 µg target plasmid and 11 µg carrier pUC18
DNA or 8 µg target plasmid and 8 µg cotransfected effector

plasmid, pGR150B65.

Four hours after the DNA was added, the

cells were shocked by adding to their medium 1 ml 15%
glycerol in minimal essential medium for 1 minute, then the
cells were washed with PBS-A (0.14 M NaCl, 2.7 rnM KCl, 4.3 rnM
Na2HP04,
IFCS+P/S.

1.5 rnM KH2P04), and incubated further in DME+10%
Transfected cells were either superinfected with

the vhs-1 mutant of HSV-1 at multiplicity of infection of 3
for 20 hours after transfection, and harvested 26 hours later
for CAT assay, or directly harvested for CAT assay 44 hours
after DNA transfection.
CAT assay
The procedure of Nordeen et al. was used as a rapid,
sensitive and inexpensive assay for chloramphenicol acetyltransferase activity66.
Cell extract preparation.

At 26 hours postinfection

for virus superinfected cultures, the cell monolayers were
washed twice with cell wash buffer (40 rnM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM EDTA), scraped from the cluster dishes and
sedimented by low speed centrifugation.

Cell pellets were

resuspended in 100 µl 250 rnM Tris-HCl, pH 7.8.

The cells

were frozen at -20°C, thawed at room temperature for four
times and then debris were removed by centrifugation at
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10,000 rpm at 4°C for 10 minutes.

Cell extracts were stored

at -70°C.
CAT enzyme assay. Chloramphenicol, ATP, bacterial
chloramphenical acetyl transferase, S-acetyl coenzyme A
synthetase, and coenzyme A were purchased from Sigma Chemical
Company.
Reaction mixtures containing 31.5 µl of 4x Assay buffer
(400 mM Tris-HCl pH 7.8, 24 mM MgCl2, 300 mM KCl) were
thoroughly mixed with

0.008 units of S-acetyl coenzyme A

synthetase, 5 µ1 of 0.78 µCi/µl 3H-Na0Ac, 10 µl of SmM CoA, 4
µl of lOOmM ATP and 0.5 µ1 of Chloramphenicol in a total
volume of 95 µl. S-acetyl coenzyme A synthetase were added
last to initiate the reaction.

The reaction mixtures were

incubated at 37°C for 30 min to generate labeled acetyl CoA.
Thirty ul of cell extract was added and reaction mixtures
were further incubated for 2 hours.

The labeled

chloramphenicol was extracted by vigorous shaking with 1 ml
benzene.

The benzene and aqueous phases were then separated

by centrifugation in a microcentrifuge at 4°C for 15 minutes.
An 800 µ1 aliquot of the benzene phase was placed in a
plastic scintillation vial and dried by evaporation in a fume
hood overnight.

The residue was counted in 3 ml of

scintillation fluid and radioactivity determined in a liquid
scintillation spectroscopy, Beckman LS 9000.

The CAT assay

results were also confirmed by thin-layer chromatography and
autoradio-graphy.

After the 800 µl aliquots of the benzene
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phase were dried in a fume hood overnight, they were
redisolved in 50 µ1 of benzene and spotted on a KODAK silica
gel thin-layer chromatography (TLC) plate.

Chromatography

was carried out with chloroform-methanol (95:5) as the
solvent.

The TLC plate was dried in a fume hood overnight

and then exposed to Fuji RX X-ray film to visualize the
acetylated chloramphani-col.

After autoradiography, the

labeled region of the TLC plate were excised and the
radioactivity determined by Beckman LS 9000 liquid
scintillation counter.

CHAPTER IV
DISCUSSION
The Complexes Formed by VPS LBS and YYl
Promoter activities are regulated by the interaction of
numerous site-specific DNA-binding proteins with their
recognition sequences.

A fundamental property of many site-

specific DNA-binding activators is their ability to stimulate
transcription synergistically with other factors which
recognize the same sequence or adjacent sequences.

In the

mobility shift assay in this study, two DNA-protein complexes
were formed with both mock-infected and HSV-1 infected
nuclear extracts.

Although the VPS promoter is a typical

eukaryotic promoter and requires three immediate-early
proteins (ICPO, ICP4, and ICP27) for transactivation, there
was no viral specific complex formed.

The mobility shift

result indicated that a cellular factor (or factors)

is

involved in the formation of the complexes and that the HSV-1
immediatly-early proteins do not binds directly or only
weakly bind to the VP5 promoter.
Other HSV-1 promoters from different kinetic classes,
and promoters from other viruses and some cellular genes,
were tested in competition assay.

Most of them were not able
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FIG. 11. Gel mobility shift analysis of the VPS promoter.
Various amount of nuclear extracts from either uninfected
or HSV-1 infected HeLa cells were reacted with 0.1 ng of
VPS promoter fragment (-4 to -168 bp relative to the cap
site, end labeled with[a-32p]dCTP). Amount of nuclear
extracts used, in micrograms of protein per reaction, and
positions of the two major complexes (A and B) formed and
free probe (P) are indicated.
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were either mockinfected or infected with HSV-1 for 8 hours
(Fig. 11).

The reaction products were analyzed by

electrophoresis on polyacrylamide gels.

Two complexes were

formed with both mockinfected or HSV-1 infected nuclear
extracts.

The larger complex, of lower mobility, was

designated complex A and the smaller one was designated
complex B.

Although gene expression studies of immediately-

early gene mutants of HSV-1 have shown that

~y

gene

expression required viral IE proteins67, no viral specific
complex was observed in this experiment.

IE proteins may

indirectly bind to VPS promoter or binds weakly to VPS
promoter.

This mobility shift assay result also indicates

that some cellular factors are involved in forming the two
complexes.
To determine the promoter specificity of these
complexes, a series of competition binding assays was carried
out by using a number of different viral promoters.

A

HindIII/SalI fragment(-4 to -168 bp) of VPS promoter labeled
with [a-32p]dCTP was used as probe, and the competing, nonlabeled DNA fragments used were promoters from HSV-1 genes of
different kinetic classes.

Since the protein binding sites

LBS previously identified in the VPS promoter overlapped with
a nuclear factor-1

(NF-1) consensus sequence, a DNA fragment

containing the NF-1 sequence of adenovirus-2 was also tested
in the competition binding assay (see Table 1) .

The results

of these experiments (some presented in Figure 12) indicate

TABLE 1. VARIOUS SEQUENCES TESTED IN THE MOBILITY SHIFT ASSAY

Competitor Fragment and Source

1. 430 bp PstI/KpnI fragment of pCA23
190 bp AvaII fragment of pCA23
2. 370 bp EcoRI/SstII fragment of pDII
3. 200 bp HindIII/KpnI fragment of p2.7-CAT
4. 214 bp PstI/PvuII fragment of pHSV-106
5. 620 bp SmaI/PstI fragment of HSV-106

Content

a-TIF promoter
NF-1 site of adenovirus-2
UL14/15 (2.7
5.2 kb

py

py

gene) promoter

gene promoter

HSV-1 gH promoter
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that none of the promoter fragments I tested compete with the
VP5 promoter DNA in the formation of complexes A and B.
Likewise, the failure of the adenovirus-2 NF-1 DNA fragment
to compete suggests that the NF-1 consensus sequence present
on the VP5 promoter is not responsible for complex A and B
formation.

However, Millette's

results68 showed that the

HSV-1 promoters gD and gB, and an internal fragment of the
UL37 gene competed with VP5 promoter to form the complexes.
These results, taken together with others from Millette's
lab, indicate that the observed complexes are very likely
specific for the VP5 promoter and certain ~y genes of HSV-1
(see Table 2).
To determine the boundaries of the VP5 DNA sequences
involved in the formation of complexes A and B, two
subfragments of the VPS promoter region were used, VPS(4/-75), containing the sequence from -4 to -75 and VP5(-50/168), containing the sequence from -50 to -168 relative to
the mRNA cap site (see figure 13) .

They were excised from

plasmid pVP5(-4/-75)CAT and pVP5(-50/-168)CAT respectively.
In the first experiment, a [a-32p]dCTP labeled HindIII/SalI
fragment of the VP5 promoter, VPS(-4/-168), was used as
probe, and 50-fold molar excess amount of VP5 promoter
subfragments were served as competitors.
and VP5(-50/-168) competed.

Both the VP5(-4/75)

In the second experiment, a

[a-

32p]dCTP labeled VP5(-50/-168) fragment was used as probe
while 50-fold molar excess amount of non-labeled VPS(-4/-75)
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FIG. 12. Competition of VPS promoter complex formation by unlabeled DNA fragments. 32P-labeled VPS(-4/168) promoter and 3.7 µg of protein of infected HeLa nuclear extract presented in all reactions. All
Lane 1 were probe only. Lane 4 in A, lane 2 in B and C, are positive control, which 40-fold molar excess
of unlabeled VPS(-4/-168) were used as competitor. A. Lane 2 and 3, 20-·and 40-fold unlabeled UL14/UL15
fragment as competitor, respectively.
B. lane 3 and 4, 20- and 40-fold 190 bp a-TIF promoter as
competitor; lane 5 and 6, 20- and 40-fold 430 bp a-TIF promoter as competitor. C. lane 3 and 4, 20- and
40-fold unlabeled 370 bp fragment which contains adenovirus-2 NF-1 site as competitor.

Table 2. Competition of VPS Promoter Complex Formation by
Unlabeled Viral and Cellular DNA Fragments

DNA fragments showing:
Source of
fragments
No competition

HSV-1 DNA

gH,

gC

(y)

UL14/15
UL24
UL37 -137
UL46
VPl 6

(~y)

TK
UL40

(p)

ICP4 7

Adenovirus
type-2 DNA

(a)

Major late promoter
NF-1 site

Cellular DNA

Competition

E-globin promoter

VP5

(~y)

gD (~y)
gB +136 (py)
UL 3 7 + 7 5 0 ( p or py)

VP5(-4/-168)
CAT box

Sal I

I

NF-1 consensus

LBS

sequence

SP1

lccAATIHrfGGACCAGGGCC~TCITGAA

-1 68

-107

-101

-85

V P5 {- 5 0I - 168)

IGGGCGGH TATATAAI
-38

- 71

er

Hind 111

TATA box

-28

-25

-4

- 18

LBS

I

ICCAATIHrfGGACCAGGGCC~ TCITGAA-1

-1 68

-50

LBS

VP5(-4/-75)

lGGCC1 TCITGAA

I

IGGGCGGH TATATAAI

-75

FIG. 13.

Diagram of VPS(-4/-168) promoter and its subfragments, VPS(-4/-75)

VP 5 ( - 5 1 I -1 6 8 ) .
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and
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served as competitor; the VP5(-4/-75) fragment showed good
competition (see figure 14) .

These results indicate that

complexes A and B involve DNA sequence located in the overlap
region of the two VP5 promoter subfragments, the sequence
from -50 to -75 relative to the cap site.
DNase I footprinting and orthophenanthroline-cu+
analysis68 confirmed the location of complexes.

The results

show that Complex A involves the sequence from -64 to -75,
and complex B involves sequence from -63 to -76 relative to
the VP5 cap site.

Both complexes encompass a common core

promoter sequence GGCCATCTTGAA , designated the Leaky-late
Binding Site (LBS), located from -64 to -75 relative to the
cap site (see figure 15).
ANALYSIS OF MUTANTS
Complex formation by the mutated VP5 promoters
To assess the role of the VP5 promoter Leaky-Late
Binding Site (LBS) in the transcriptional regulation of the
VP5 gene, a series of mutated VP5 promoter constructs were
generated from pVP5(-4/-168)CAT by deletion and insertion
around the protein binding site LBS.

The isolation procedure

involved, in brief, opening pVP5(-4/-168)CAT at a BstNI site,
exonucleolytic digestion with nuclease BAL 31, connecting an
8 bp BglII linker, and ligating the appropriate fragment back
together (See Materials and Methods) .

The mutant constructs

isolated and used in these studies are shown in Figure 16.
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FIG. 14. Competition binding assay between the VP5(-4/-168) promoter and its
subfragments. A. VP5(-4/-168) as probe. Lane 1, probe only, without competitor; lane
2-4, unlabeled 50-fold molar excess of VP5(-4/-168), VP5(-51/-168), and VP5(-4/-75),
respectively. B. VP5(-51/-168) as probe. Lane 1, probe only; lane 2, unlabeled SO-fold
molar excess of VP5(-51/-168); lane 3 and 4, unlabeled 20 and SO-fold molar excess
VPS(-4/-75). 3.7 µg of protein of infected HeLa nuclear extract presented in all lanes.
Poly(dI-dC) were used for nonspecific binding.
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They were construct #2 in which sequence from -83 to -93 was
deleted,

#6 which contained an 8 bp Bgl II linker insertion

between -80 to -81 thereby splitting the NF-1 consensus
sequence,

#10 in which the sequence from -70 to -93

containing NF-1 consensus site and half of LBS was deleted,
and #13 in which the NF-1 consensus site and the LBS were
completely deleted.
Mutated VPS promoter from constructs #2,

#6,

#10 and #13

were tested as competitors in competition binding assay to
determine the relation between promoter sequences and the
ability to form complexes A and B.
radiolabeled probe to the
Figure 17).

The molar ratio of

competitor was 1:20 and 1:40,

(See

The results of these experiments showed that the

mutated VPS promoter of mutant constructs #2

(data not shown)

and #6 were capable of competing as well as the wild-type VP5
promoter, whereas the mutated VPS promoter of #10 only
partially competed and that of #13 completely failed to
compete.

These data indicate that the deletion of sequence

from -83 to -93 in construct #2 and the 8 bp insertion
between -80 and -81 in #6 does not affect the formation of
complexes A and B. Deletion of sequence from -70 to -93 in
construct #10 partially affects the formation of both
complexes and the deletion of sequence from -59 to -93 in
construct #13 completely eliminates complex formation.
Therefore,

sequence from -80 to -59 is most likely involved

in the formation of both complexes directly.
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FIG. 17. Competition binding of labeled VPS promoter versus unlabeled mutated VP5
promoter fragments. Gel mobility shift assay was carried out with 3.7 µg of protein
of infected HeLa nuclear extract. A, B, and P, complexes A and B and free probe
respectively; lane 1, free probe; lane 2 and 9, 32p labeled VPS(-4/-168) without
competitor. For the remain lanes, 20- and 40-fold molar excesses of the indicated
wild-type or mutated VPS promoter fragments were used as competitors.
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The promoter activity in transient expression assay
To analyze the role of the complexes in the regulation
of VPS gene expression, the wild-type VPS promoter (sequence
-4 to -168) and mutated VPS promoters were tested in
transient expression assays with or without viral transacti vation to investigate the effects of the mutation on
promoter ability to drive expression of the bacterial
chloramphenicol acetyl transferase gene at both basal level
and induced level.
Hela cells were transfected with either wild-type VPS(4/-168}-CAT or mutated VPS promoter constructs.

The cells

were either harvested 45 hours after transfection, or they
were superinfected with the vhs-1 mutant of HSV-1 KOS strain
24-26 hour after transfection, and then harvested 26 hours
later.

These results are presented in Figure 18.

Without

viral transactivation, both wild type VP5 promoter and
mutated VPS promoters were basically inactive.

The levels of

CAT expression driven by these promoters were essentially
same as that in the untransfected cell.

With virus

superinfection, however, CAT activity of VP5(-4/-168}CAT
increased 424 fold whereas construct #6 having an 8 bp
insertion disrupted the NF-1 consensus sequence increased 351
fold.

As with construct #6,

the deletion in construct #2

had only a small effect in CAT activity(data not shown}.
Deletion of half of LBS (#10} reduced the transactivaion
level to 92 fold whereas deletion of all LBS (#13) produced
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represents induced levels. Number on the bar graph
indicate fold-induction over uninduced levels. Average
uninduced CAT levels was 5.6 pmol of acetylated
chloramphenicol. The data represent averages of a minimum
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only 51 fold induction by superinfecting virus.

Therefore,

deletion of LBS resulted in about 8-fold reduction in the
level of viral transactivation of the VP5 promoters.

These

results suggest that the LBS may activate the VPS promoter by
binding to the cellular factor and this is required for the
maximum VPS expression under viral superinfection.
Early studies HSV-1 mutations in other laboratories
have reported that three HSV-1 IE genes (encoded ICPO, ICP4,
and ICP27) were required for VP5 promoter activation.

The

requirement of all three viral proteins was tested in the
transient expression assay.

Plasmid pGR150B contains the

immediate-early gene ICPO, ICP4 and ICP27.

Plasmid pGR90

contains ICPO, ICP4 and ICP47 gene, and pGR162 contains ICP27
gene only.

Plasmid pVP5(-4/-168)CAT along with one of the

above plasmids were used to cotransfect the cells.

The CAT

activity induced by pGRlSO was 69.8 times over the uninduced
level, whereas the CAT activities induced by either pGR90 or
pGR162B remain about the same as the uninduced level
Fig. 19).

(see

This comfirmed the necessity for all three

immediately-early viral proteins in VPS transactivation.
The involvement of LBS in the viral proteins transacti vation process was tested in further transient expression
assay.

Cotransfected plasmid, pGRlSOB provided the three

viral immediately

prot\~in:3

(ICPO, ICP4, and ICP27) required

for activating late gene promoters

(see figure 19) .

The

results showed that transactivation by IE genes increased CAT
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activity of pVP5(-4/-168)CAT 69.8 fold over the uninduced
level, whereas #6 increased it 30.5 fold,

#10 increased it

13.6 fold, and #13 increased it only 9.6 fold.

Thus deletion

of the LBS resulted in a 7.1 fold reduction in gene
expression relative to that of the wild type VPS promoter.
These results indicate that even though the LBS has not been
shown to directly associate with viral proteins, it is
required for optimal level of transactivation by
superinfecting HSV-1 or cotransfected HSV-1 IE proteins.

In

addition, the LBS sequence appears to have no effect on the
uninduced level of promoter activity.
A Computer search of GeneBank has shown that homologies
to LBS exist in many viral genes and cellular genes. The
homologies and their locations are listed in Table 3.

Table 3. Promoter Sequences Homologous to the VPS LBS Sequence

Gene

Viral gene
HSV-1
VPS
gD
gB
UL46
UL37

UL38
HSV-1 LBS
consensus
sequence
CMV

MCMV IEl

DNA sequence

GGGCCAlCl::CGA!.TG
GGGCCATtTTacg
tGGCCATCgTcgA
GGcCCcTCtttgAT
GGGCCATCggG
GcGCCATCTTGA
GGGCCATtTgG
GGGCCATtTgG

vzv

VPS (UL40)
UL41

Competition
against VPS

-70 (cap)
-63 (cap)
+137 (cap)

+
+
+

-249 (cap)
-55 (ATG)
+750 (cap)
-137 (cap)
-172 (ATG)

+

GGCCA:;cNTT

A

A

GCCAT·cTTGG
GCCATgTAct

HCMV IE68

Location
ralative to cap or ATG

GCCATNT

3 sites +133 to +180(cap)

-247 (cap)
multiple copies in enhancer/promoter

CCA-CTTGAATc
GCCgTCTTGAATc

-25 (ATG)
coding region

GCCATCTTGAtTG

overlap ATG

Human papillomovirus-5, ORF Ll
Retroviruses
Murine leukemia
virus
SRV-1
SRV-2
RAV-0
SIV
Adeno-associated
virus PS
Cellular genes
Immunogloblin
heavy chain
c-myc (murine)
Skeketal o:-actin

GGaCCATCT
GCCATCTTGAATGC
GCCATCTTGcATcC
CCATCTTGAA
GGCCtTCTTaA

-180
-140
-140
-145
-131

(cap)
(TATA)
(TATA)
(cap)
(cap)

+

tctCCATtTTGA (YYl site) +l (cap)
GcGaCATtTTGc (YYl site) -60 (cap)
GGCCATCTTGA (µEl site)
GaCCTtTTct (CFl site)
cGCCATgTacc

enhancer
-260 (cap)
-90 (cap)

+
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DISCUSSION
The Complexes Formed by VPS LBS and YYl
Promoter activities are regulated by the interaction of
numerous site-specific DNA-binding proteins with their
recognition sequences.

A fundamental property of many site-

specific DNA-binding activators is their ability to stimulate
transcription synergistically with other factors which
recognize the same sequence or adjacent sequences.

In the

mobility shift assay in this study, two DNA-protein complexes
were formed with both mock-infected and HSV-1 infected
nuclear extracts.

Although the VPS promoter is a typical

eukaryotic promoter and requires three immediate-early
proteins (ICPO,

ICP4, and ICP27) for transactivation, there

was no viral specific complex formed.

The mobility shift

result indicated that a cellular factor (or factors)

is

involved in the formation of the complexes and that the HSV-1
immediatly-early proteins do not binds directly or only
weakly bind to the VP5 promoter.
Other HSV-1 promoters from different kinetic classes,
and promoters from other viruses and some cellular genes,

were tested in competition assay.

Most of them were not able
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to form the complexes, except the gD promoter, a fragment
from the nontranslated leader region of gB, and a UL37 gene
fragment
the HSV-1

(see Table 2) .
~y

These genes, like VP5, all belong to

kinetic class.

Further studies from the

Millette labortory showed that the promoters of HSV-1 gB, go
and human c-myc gene competed with the VPS promoter by
binding to the same protein68.
There is a consensus nuclear factor-1

(NF-1) binding

site upstream of the LBS that partially overlaps with the
LBS.

NF-1 was originally isolated from HeLa nuclei as a host

factor required for efficient initiation of adenovirus DNA
synthesis in vitro69.

Subsequently, NF-1 was shown to be

identical to the cellular factor CTF (CCAAT-binding
transcription factor)

and play a role in transcription70.

A

number of NF-1 binding sites have been identified upstream of
various cellular and viral genes.

In this study, partial

deletion of LBS and NF-1 consensus binding site in mutant #10
reduced complex formation, and complete deletion of LBS and
NF-1 consensus binding site in mutant #13 resulted in
elimination of the complexes.

The involvement of NF-1

consensus sequence to the protein-DNA complexes was tested in
competition binding assay.

A forty-fold molar excess of a

DNA fragment which contains an adenovirus-2 NF-1 site and
origin was unable to compete with the VPS promoter sequence
to form the complexes.

Also, An 8 bp insertion in the middle

of the NF-1 consensus site of mutant #6 did not change the
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ability of VPS promoter to form the complex.

Therefore, it

is unlikely that the NF-1 is involved in the formation of
complex A and B ..
By treating the DNA/protein complexes with V8
endoprotease, Millette and Mill's partial proteolysis study
revealed the similar subcomplex patterns among the complexes
formed by VPS promoter, gD promoter or human c-myc promoter
with nuclear extract, and complexes formed by VPS promoter
with YYl protein71.

They also showed that a monoclonal

antibody to YYl inhibited formation of complexes A and B.
Their result indicated that the protein which forms the
complexes A and B is cellular factor YYl.
Based on following observation in their laboratory,
Millette and Mills suggested that the smaller complex (B)
results from proteolytic cleavage of the YYl protein that
forms complex A, and either two forms of YYl exist in the
cell or they were formed during nuclear extract preparation:
1) DNase I and orthophenanthroline-cu+ footprint analysis68
showed that complex A and B formed over a core sequence
GGCCATCTTGAA (LBS) located from -64 to -75 relative to Cap
site.

2) A radiolabeled oligonucleotide containing only the

LBS site formed both complexes.

3) V8 endoprotease digestion

of the nuclear extract complexes resulted in the same pattern
of subcomplexes as that observed with the YYl complex.
monoclonal antibody to YYl inhibited formation of both
complexes.

4) A
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The Effect Of LBS In VP5 Transactivation Of Viral Factors
Previous studies of Smiley and Everett using DNA
transfection showed that the VP5 promoter was relatively
inactive in uninfected cells, but it was effectively
transactivated by a superinfecting virus, HSV-1, or by three
immediately early gene products: ICPO,

ICP4 and ICP27.

In Costa and Wagner's early study, the activities of
different length VP5 promoters were tested in transient
expression assays.

The VP5 promoter sequence from +1 to -75

had detectable activity in uninfected HeLa cells, whereas the
VP5 promoter sequence from +1 to -125, +1 to -168, or +1 to
-650 were completely inactive in transfected HeLa cells in
the absence of HSV induction.

However, with HSV-1 infection,

even though the the VP5 promoter sequences +1 to -75 was
sufficient to allow expression with HSV superinfection, it
induced at least 10 fold less CAT expression than that of
VP5 promoter from +1 to -125, +1 to -168, or +1 to -650.

In

addition, no more than 125 bp of VP5 promoter was found to be
sufficient for the maximum expression.

This suggested that

some feature of the VP5 promoter sequence between -75 to -125
blocked the uninfected cell's ability to recognize the VP5
promoter in the CAT expression assay and that this region of
the VPS promoter may also be involved in achieving full

activity from this promoter after HSV superinfection55.
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In my research project, wild-type VPS promoter(-4/-168)
and mutated VPS promoters, ranged from -59 to -93 relative to
cap site, were tested in transient expression assays to
elucidate the effects of the mutation on promoter activity.
Wild type VPS promoter and all mutated VPS promoters have
undetectable activity in uninfected cell.

This result

further suggest that the sequence from -94 to -125 may have a
blocking or repressing effect.

CAT gene expression driven by

wild-type VP5 promoter increased 425 fold with HSV-1
superinfection over that of uninfected control. Insertion of
8 bp in the middle of NF-1 consensus sequence, as well as
deletion from -82 bp to -93 bp in #2, slightly reduced CAT
gene expression.

Deletion of complete protein binding site

and NF-1 consensus sequence resulted in only 51 fold
induction. This amounted to a 8.3-fold reduction in viral
transactivation, and a level of CAT gene expression that was
only 13% that of wild type.

Similar results were obtained

from co-transfection of VP5 promoters with a plasmid
containing genes for three HSV immediately-early proteins,
ICPO,

ICP4, and ICP27. These results suggest that LBS plays

an important role in optimal level VPS gene expression.

The

increase in expression mediated by the NF-1 binding site may
be is additive with, and independent of, the enhancement by
the VPS LBS.

The significance of each should be tested in

transient assay by deletion of either NF-1 consensus site or
the protein binding site, LBS.

Complete deletion of LBS in
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VPS promoter did not reduce promoter activity to the control
level. This suggested that another region of VPS promoter
also must be involved in the transactivation process, and
that interaction of multiple factors

may be required for

maximal transactivation of the VPS promoter.
A Computer analysis of GeneBank have shown that
homologs of LBS exist in many viral genes and cellular genes.
The homologs and their locations are listed in Table 3. In
HSV-1, several late genes showed sequences highly homologous
to LBS.

Millette's data showed that three other HSV-1

py

promoters(gB, gD, and UL37) competed for the factor binding
to LBS; two potential
compete.

PY

promoters (UL14/15, UL24) did not

In Everett's early study of gD promoter, deletion

analysis showed that the promoter region which contains the
LBS homolog was very critical for viral transaction of the
gene.

The VPS promoter of Varicella-Zoster virus, and the

late promoter of human papillomovirus-5 also contain LBS
homologs.
The most interesting finding is the existance of LBS
homologs in the long terminal repeat of many retroviruses.
These include both simian retrovirus 1 which causes simian
acquired immune deficiency syndrome (SAIDS), and simian
retrovirus 2 which induces retroperitoneal fibromatosis in
addition to SAIDS.

These LTRs contain 8 to 14 bp of LBS

homologies located about 130-150 bp upstream from the mRNA
start site.

Millette's laboratory found that a fragment of
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the SRV-1 LTR that contains a 14 bp perfect match to the VPS
LBS formed two complexes of similar mobility to the VPS
complexes, and an oligonucleotide containing the VPS LBS
effectively competed with the SRV-1 fragment for cellular
protein binding68.

LBS homologies also occur in the long

terminal repeat of human AIDS virus HIV-1 and a human retroprovirus, and deletion studies have shown this region of the
long terminal repeat may play a role in transcriptional
regulation.

Herpes simplex virus 1 and 272, cytomegalo-

virus 73, and human herpesvirus 674 are among of a number of
viruses have shown be able to activate gene expression driven
by the HIV long terminal repeat and enhancer.

Even though no

specific binding between ICPO and HIV-1 LTR found, the
transfection study of Pitha et al. have showed that ICPO can
activate the HIV-1 long terminal repeat promoter region and
the effect of ICPO can greatly enhanced in the presence of
cellular factor NF-KB75.

The Spl sites located on the HIV-1

LTR also served as target sites of transactivation by HSV176.

The next interesting question is, does the VPS LBS

homolog in the HIV long terminal repeat play a role in the
transactivation of HIV.
The recognition site for common factor I

(CFl)

in the

cellular immunoglobin heavy chain enhancer, skeletal a-actin
promoter, and c-myc promoter also showed homologies with LBS.
CFl, a protein which binds the upsteam of the murine c-myc Pl
promoter, was identified by mobility shift assay and
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footprint assay77.

The CFl binding activity was found in all

cultured cells and normal tissues tested78.

Riggs et al.

have recently published results showing that CFl is identical
to yy179.
YYl, also known as NF-El, UCRBP, and B,
ly expressed zinc finger protein.

is a ubiquitous-

The binding sites for YYl

are widely distributed in many cellular and viral
promoters80.

In many instances, YYl act as a transcriptional

repressor81,82, e.g. in the adeno-associated virus PS
promoter, immunoglobulin K3' enhancer, and c-fos promoter,
etc., whereas in other cases it appears to be an activator of
transcription83, for example, in the c-myc promoter, and IgH
intronic enhancer.

In Natesan and Gilman's paper, they

presented the evidence that YYl regulates the activity of the
c-fos promoter primarily through an effect on DNA structure.
YYl binds to the promoter and induced a phased DNA bend at
three sites.

YYl repressed the c-fos promoter activity, but

activated the same promoter when the YYl binding site was
reversed.

They concluded that the major function of YYl in

c-fos promoter is to bend DNA to regulate contact between
other proteins84.

In the case of HSV-1, it is possible that

the bending of VP5 promoter caused by YYl enhances the
interaction between general transcription factor and Spl or
CAT box binding protein.

Finally, there are several reports

about the physical interaction between YYl and Sp185.
suggest that Spl may exert its effect on VP5 promoter

This
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activity in an indirect way by affecting how YYl interacts
with VPS.
DNA bending and looping play an important role in the
regulation of transcription, replication and recombination in
bacteria86, 87.

Many mammalian transcription factors have

been reported bend DNA88,89.

Natesan and Gilman suggested

that some transcription factors, e.g. YYl, may have no
intrinsic activation or repression function of their own, but
may induce structural changes such as bends in the DNA helix
to facilitate other protein-DNA interaction.

It will be

interested to investigate the YYl function when the LBS
orientation reversed.
Some of the VPS LBS homologs are found in introns or
the coding sequences of other viral genomes and cellular
genes.

It is hard to determine the significance at this

point, but an increasing number of intragenic elements which
affect gene transcription have been reported90, and some
researchers have reported regulatory elements that are
located within protein-encoding sequences91.
In summary, the research findings in this project are
presented as following: 1) Two DNA-protein complexes were
formed with the HSV-1 VPS promoter. The VPS regulatory
sequence, LBS, is responsible for the formation of these
complexes, and the cellular protein involved, later proved by
Millette and Mills, is YYl.

2) Mutation analysis showed that

the LBS is required for maximum levels of VP5 transactivation
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either by superinfecting HSV-1 or by cotransfected IE HSV-1
genes,

ICPO,

ICP4, and ICP27.

3) Homologs of the LBS occur

throughout the HSV-1 genome and other viral genome, as well
as some cellular genes.

Millette and Mills showed HSV-1 gD,

gB, and UL37 genes also form the complexes with YYl. This
suggested that the regulation in VPS is very likely relevant
to several other HSV-1 ~y genes.

Some of the homologs

studied in other laboratories, for example, the homologs in
adeno-associated virus PS promoter and in immunoglobulin
heavy chain enhancer, have shown to play an important role in
the transcription regulation.
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